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A B S T R A C T
Dogs develop only some of the components of the human metabolic syndrome (MetS). Thus, in order to study
possible MetS-related alterations in dogs, human MetS criteria were adapted to define canine MetS or so-called
obesity-related metabolic dysfunction (ORMD). The main objective of this study was to identify changes in the
salivary proteome of obese dogs with ORMD in comparison with obese dogs without ORMD which may con-
stitute potential salivary biomarkers for assessing ORMD. In a first phase, 12 adult obese dogs with ORMD
(N=6) and without ORMD (N=6) were included in the study. Subsequently, and with the aim of validating
and strengthening the results, additional 12 obese dogs (6 with and 6 without ORMD) were tested in an in-
dependent experiment following the same protocol. Saliva samples were subjected to a quantitative proteomics
analysis and the levels of nine salivary proteins were found to be significantly different between groups, among
them those which had greatest fold-change were proteins involved in glycolysis and oxidative stress. In con-
clusion, despite metabolic syndrome to include different combinations of diseases, the observation of differences
in salivary proteome suggests a potential of this fluid to understand the pathophysiology of the disease.
Significance: This is the first study evaluating proteomes of saliva in dogs, as a non invasive sample, in order to
increase knowledge about the metabolic/physiopathological changes related to obesity-related metabolic dys-
function (ORMD) together with the identification of potential biomarkers for its diagnosis. As approximately
20% of dogs with naturally occurring obesity were described to suffer ORMD associated with insulin resistance
and hypoadiponectinemia, the fact that indicate possible links between ORMD and associated diseases.
1. Introduction
In humans, the term ‘metabolic syndrome’ (MetS) describes a clus-
tering of obesity (especially visceral obesity), hypertension, insulin re-
sistance or hyperglycaemia, and hyperlipidaemia, especially increased
fasting triglycerides and decreased High-Density Lipoprotein
Cholesterol (HDL-C) [1]. The MetS itself causes no clinical signs, but
comprises a set of important risk factors for diseases that cause mor-
bidity and mortality in humans, including non-alcholic liver disease,
cardiovacuscular disease, stroke, and type 2 diabetes [2]. Dogs develop
some of the components of the human MetS: obesity [3], insulin re-
sistance [4], increased blood pressure [5], and hyperlipidaemia [6].
Nevertheless, although liver alterations in canine MetS were reported
[7], the most important consequences of the MetS in humans such as
type 2 diabetes (T2D), stroke and coronary heart disease, either do not
exist or are very rare in dogs suggesting that dogs could have protective
mechanisms or that dogs lack pathophysiological elements present in
humans [8]. In order to study possible MetS-related alterations in dogs,
human MetS criteria were adapted to define canine MetS or so-called
obesity-related metabolic dysfunction (ORMD) [9]. Approximately 20%
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of dogs with naturally occurring obesity were described to suffer ORMD
[9] associated with insulin resistance and hypoadiponectinemia [9–11].
Saliva has gained interest for biomarker identification, mainly due
to the non-invasive nature of its collection, at the same time that it
contains glandular and blood-born molecules whose levels can change
under different conditions [12]. In humans, various MetS biomarkers
were found in saliva samples, such as salivary HDL-C and fasting glu-
cose levels, adipokines (such as adiponectin, leptin, resistin) and
proinflammatory markers such as C-reactive protein (CRP), insulin,
ghrelin, tumour necrosis factor alpha (TNF-α), interleukins, either in
adults or adolescents and children [13–15]. The results of those studies
provide useful information about the development of this metabolic
disease and establish that saliva may be a fluid of interest in the study of
this syndrome [14].
In present study, we hypothesized that dogs with metabolic dys-
function could have a different salivary protein composition compara-
tively to dogs without ORMD. Thus, the main objective of this study
was to identify changes in the salivary proteome in obese dogs with
ORMD that can help to understand the metabolic/physiopathological
changes related to this condition together with the identification of
potential biomarkers for its diagnosis.
2. Materials and methods
2.1. Ethical note
The study protocol was approved by local and regional Research
Ethics Committees (323/2017 and A13170806, respectively).
2.2. Animals
A total of 24 adult dogs of different breeds were included in this
study. Saliva samples from six castrated adult obese dogs without
ORMD (non-ORMD group) and six castrated adult obese dogs with
ORMD (ORMD group) were used for the proteomic screening while the
remaining animals (six with and six without ORMD) were further used
to validate data obtained in the initial screening, as detailed in Section
2.7. All animals were client-owned dogs brought for routine check-up
or vaccination to different private veterinary clinics of Murcia Region,
Spain. All dogs were evaluated for their general health status and only
those that did not present signs of other than obesity diseases, as based
on physical examination, CBC and biochemistry analyses. In addition,
CRP was measured in all dogs in order to discard active inflammation;
only dogs with CRP < 12mg/L were considered for the inclusion in
the study. Body condition score (BCS) was determined using a validated
5-point body condition score system (were 1 means very thin, 2 – un-
derweight, 3 – ideal weight, 4 – overweight, 5 – obese) in both groups
[16]. The descriptive clinical data of dogs from both groups are detailed
in Table 1.
2.3. Definition of obesity-related metabolic dysfunction
Dogs were considered as having ORMD if met previously described
criteria [9]: (a) BCS 4-5/5; and (b) any two of the following: 1) plasma
triglycerides> 200mg/dL; 2) plasma cholesterol> 300mg/dL; 3)
systolic arterial presure (SAP)> 160mmHg; 4) fasting plasma glu-
cose> 100mg/dL, or previously diagnosed diabetes mellitus [9].
Blood pressure in all dogs was measured non-invasively using an
oscillometric method. All dogs were fully conscious. A cuff of the ap-
propriate size (e.g. the cuff chosen had a width of ~40% circumference
of the leg) was placed on the right forelimb. Once the dog was calm and
still, at least five systolic arterial pressure (SAP) readings were taken
and averaged.
2.4. Serum analysis
Serum total cholesterol, triglycerides and glucose were measured in
an automated biochemistry analyser (Olympus AU600, Beckman
Coulter, Brea, USA) using commercially available reagents and fol-
lowing the instructions of the manufacturer.
2.5. Saliva analysis
2.5.1. Saliva collection
Saliva samples were collected as previously described [17]. A
sponge was placed in each dog's mouth, left in contact with the cheek
mucosa for 1–2min, and was then placed into the Salivette device for
centrifugation (3000g, 10 min, 4 °C). After centrifugation, saliva was
transferred to 1.5mL polyethylene tubes and stored at −80 °C until
analysis.
2.5.2. Total protein concentration
Bradford method protein assay with BSA as the standard protein
(Pierce Biotechnology, Rockford, IL, USA) was performed to determine
the total protein concentration of each sample. Standards and samples
were run in triplicate, in 96 wells microplates. Absorbance was read at
600 nm in a microplate reader (Glomax, Promega).
2.5.3. Protein digestion in solution
The volume of each saliva sample correspondent to a total of 50 μg
of protein was added to 10 μL of 6M Urea 50mM ammonium bi-
carbonate (AB). Then 1 μL of NaOH 0.5M was also added to adjust pH
to 8–8.5. To perform the reduction 1.43 μL of dithiothreitol (DTT)
700mM was added and the samples incubated for 1 h at room tem-
perature. Then alkylation was made adding 4.29 μL of iodoacetamide
(IAA) 700mM, with a posterior incubation of 30min at room
Table 1
The baseline characteristics of dogs included in salivary proteomic and validation studies with and without obesity-related metabolic dysfunction (ORMD).
Variable Animals included in proteomic analysis Animals included in validation
Non-ORMD ORMD P Non-ORMD ORMD P
Breed German Shepherd,
Mongrel




Mongrel (2), Beagle, Scottish terrier,
Golden retriever, Boxer
Age, years 6.8 (2.5–11.0) 8.0 (3.0–11.6) 0.228 5.9 (1.8–9.1) 6.5 (2.8–10.4) 0.560
Sex 3 females and 3 males 3 females and 3 males 4 females and 2 males 3 females and 3 males
Body condition score, 5- point
scale
4–5 5 4–5 4–5
Body Weight, kg 15.8 (8.9–24.7) 12.0 (8.7–18.7) 0.254 25.8 (21.0–30.7) 18.0 (9.5–34.3) 0.571
Total cholesterol, mg/dL 244.5(209–649) 381 (269–433) 0.119 273.0 (195.8–283.5) 344.5 (319.8–373.2) 0.002
Triglycerides, mg/dL 83.5 (66.0–96.0) 88.0 (69.7–355.0) 0.333 88.0 (64.5–103.0) 90.0 (49.1–152.1) 0.898
Glucose, mg/dL 94.0 (82.0–144.0) 107.5 (90.0–111.0) 0.083 84.5 (82.5–99.8) 104.6 (101.1–108.6) 0.009
Systolic arterial pressure
(SAP)
140.9 (137.3–157.5) 139.8 (94.5–149.0) 0.329 133.2 (126.3–137.2) 144.8 (134.4–161.4) 0.127
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temperature in the dark. To quench the excess of IAA 7.5 μL of 500
mMN-acetyl cysteine (NAC) was added to the samples and incubated
for 15min at room temperature. A volume of 486.8 μL of AB 50mMwas
added to samples to dilute the urea concentration to 1M. Immediately
before trypsin digestion, 2 μg of an internal standard (MBP-GFP fusion
protein - Maltose-binding protein combined with Green Fluorescent
Protein) was added. The digestion with 5 μL of trypsin (stock 1 μg/uL)
added to each sample was done for 18 h at 37 °C. To stop digestion a
volume of 3 μL of formic acid (FA) was added to each sample.
Subsequently, a cleaning/concentration step was performed using
OMIX C18 tips (Agilent Technologies), according to manufacturer re-
commendations, by passing the mixture through the tips and eluting the
peptides by adding 70% ACN in 0.1% FA solution. The flow was
transferred to a new 1.5 mL polyethylene tube and the mixture dried
using a speed vac (LabConco, CentriVap micro IR).
2.5.4. SWATH-MS analysis – data acquisition
Saliva samples were analysed on a TripleTOF™ 6600 System
(Sciex®) using information-dependent acquisition (IDA) of pooled
samples for protein identification and SWATH-MS acquisition of each
individual sample for protein quantification [18]. Peptides were re-
solved by liquid chromatography (nanoLC Ultra 2D, Eksigent®) on a
MicroLC column Halo Fuse Core™ (300 μm ID×15 cm length, 2.7 μm
particles, 90 Å pore size, Eksigent®) at 5 μL/min with 45min linear
gradient from 5% to 30% of ACN in 0.1% FA and 5% dimethylsulfoxide
(DMSO). Peptides were eluted into the mass spectrometer using an
electrospray ionization source (DuoSpray™ Source, ABSciex®) with a
50 μm internal diameter (ID) stainless steel emitter (NewObjective). For
IDA experiments, the mass spectrometer was set to scanning full spectra
(m/z 350–1250) for 250ms, followed by up to 100 MS/MS scans (m/z
100–1500 from a dynamic accumulation time – minimum 30ms for
precursor above the intensity threshold of 2000 – in order to maintain a
cycle time of 3.3 s). Candidate ions with a charge state between +2 and
+5 and counts above a minimum threshold of 10 counts per second
were isolated for fragmentation and one MS/MS spectra was collected
before adding those ions to the exclusion list for 15 s (mass spectro-
meter operated by Analyst® TF 1.7, Sciex®). Rolling collision was used
with a collision energy spread of 5. For SWATH-MS based experiments,
the mass spectrometer was operated in a looped product ion mode [19]
and the same chromatographic conditions used as in the IDA run de-
scribed above. A set of 168 windows of variable width (containing an
m/z of 1 for the window overlap) was constructed covering the pre-
cursor mass range of m/z 350–1250. A 50ms survey scan (m/z
350–1250) was acquired at the beginning of each cycle for instrument
calibration and SWATH MS/MS spectra were collected from m/z
100–1500 for 20ms resulting in a cycle time of 3.29 s from the pre-
cursors ranging from m/z 350 to 1250. The collision energy (CE) ap-
plied to each m/z window was determined considering the appropriate
CE for a +2 ion centred upon this window and the collision energy
spread (CES) was also adapted to each m/z window.
2.5.5. SWATH-MS data analysis – protein identification and quantification
A specific library of precursor masses and fragment ions was created
by combining all files from the IDA experiments (one pool per group of
samples), and used for subsequent SWATH processing.
Peptide identification and library generation were performed with
ProteinPilot software (v5.0, Sciex®), using the following parameters: i)
search against a database composed by the Uniprot's reference pro-
teome UP000002254 from Canis lupus familiaris (85,188 entries, release
at December 2017) and MBP-GFP; ii) iodoacetamide alkylated cysteines
as fixed modification; iii) trypsin as digestion type. An independent
False Discovery Rate (FDR) analysis, using the target-decoy approach
provided by ProteinPilot™, was used to assess the quality of the iden-
tifications and confident identifications were considered when identi-
fied peptides and proteins reached a 5% local FDR [20,21]. Data pro-
cessing was performed using SWATH™ processing plug-in for
PeakView™ (v2.0.01, AB Sciex®). After retention time adjustment using
the MBP-GFP peptides, up to 15 peptides, with up to 5 fragments each,
were chosen per protein, and quantitation was attempted for all pro-
teins in library file that were identified from ProteinPilot™ search.
Peptides' confidence threshold was determined based on a FDR analysis
using the target-decoy approach and those that met the 1% FDR
threshold in at least three biological replicates were retained, and the
peak areas of the target fragment ions of those peptides were extracted
across the samples using an extracted-ion chromatogram (XIC) window
of 4min and 100 ppm error. The levels of the proteins were estimated
by summing all the filtered transitions from all the filtered peptides for
a given protein and normalized to the total intensity obtained in each
sample.
2.6. BLAST Search and Gene Ontology (GO) classification
Proteins for which differential accumulation was found by liquid
chromatography-tandem mass spectrometry (LC MS/MS) analysis were
submitted to functional classification by PANTHER (protein annotation
through evolutionary relationship) (http://www.pantherdb.org/).
Canis lupus familiaris was the selected organism. Molecular function and
biological processes pie-charts were constructed.
The BLAST program downloaded from NCBI was used for annota-
tion of “uncharacterized proteins” and to assess homologies with pro-
teins with known functions.
2.7. Validation of proteomic analysis
Saliva samples from 12 overweight/obese dogs (BCS 4–5/5) were
used to validate the findings from the initial proteomic analysis
(Table 1). Saliva samples collection and proteomic analysis were per-
formed as described for the first 12 dogs analysed (Sections 2.5 and
2.6). SWATH-MS analysis was used for salivary protein quantification
and comparison between the dogs with and without ORMD, following
the same protocol already described in Section 2.5.
2.8. Statistical analysis
Each variable (i.e., quantified protein) was tested for normality
using the Shapiro-Wilk test. Outlier's values were removed, when ex-
istent. Univariate analysis, for comparison of protein levels between
ORMD and non-ORMD groups, was performed using the Student's t-test
or the non-parametric Mann-Whitney test, depending if the data follow
a normal distribution. Statistical significance was considered for
p < 0.05 and analysis procedures were achieved using the SPSS 21.0
software package (SPSS Inc., Chicago, USA).
For Multivariate Analysis, partial least squares discriminant analysis
(PLS-DA) was used taking into account the interdependence among
proteins. Data normalization was performed by a pooled sample from
group non-ORMD and cube root transformation was used. Discriminant
variables selection was done using variable importance in the projec-
tion (VIP) with a threshold of 2.0. This was done using Metaboanalyst
4.0 [22].
For results validation, the option “Biomarker meta-analysis”, in
Metaboanalyst software was used, for confirmation of the proteins
presenting the same differences/tendencies in both sub-populations of
animals tested.
3. Results
In the present study, 300 proteins were identified in dog saliva
(supplementary table 1). These proteins have different molecular
functions, with 47.3% having catalytic activity and 37.2% being in-
volved in binding. A lesser percentage of dog salivary proteins have
diverse molecular functions, such as structural molecule activity
(6.9%), antioxidant (4.8%), signal transducer (1.6%), receptor (1.1%)
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and translation regulator (1.1%) activities. From the proteins identified,
28.3% are involved in cellular processes and 24.1% in metabolic pro-
cesses (Supplementary Fig. 1). To the best of author's knowledge, 51 of
the identified proteins were not previously reported in canine saliva
(Supplementary Table 2).
Among the identified proteins, 257 were quantified in the initial
screening (Supplementary Table 1.2) and 241 were quantified in the
validation study (Supplementary Table 1.3). The amounts of these
proteins were compared between ORMD and non-ORMD groups, first in
the sub-population initially constituted for the study (screening) and,
subsequently in the sub-population used for validation of the results.
One of the animals from non-ORMD group, of the sub-population used
for screening, was observed to be an outlier in the amounts of most of
the salivary proteins present. Moreover, looking for serum biochemical
parameters, total cholesterol reached a value higher than 600mg/dL.
For these reasons, it was removed from analysis.
Univariate analysis of the quantified proteins (both from initial
screening and validation sub-population) revealed nine proteins with
significant differential levels between ORMD and non-ORMD groups
(Table 2). These nine proteins met one of the following criteria: 1) to
present statistically significant differences (P < 0.05), between ORMD
and non-ORMD dogs, in both the screening and the validation assays; 2)
to present statistically significant differences, between groups, in only
one of the sub-populations, presenting a tendency (P < 0.1) in the
other (Fig. 1). These nine proteins were related to catalytic activity,
some participating in carbohydrate metabolism, cellular response to
stress and detoxification and with transport functions. In all cases the
protein levels were increased in the ORMD group.
The multivariate PLS-DA model shows a clear separation of the
groups (ORMD vs. non-ORMD), as illustrated for the sub-population
used for screening (Fig. 2). The proteins that contributed to this se-
paration (VIP≥ 2) in both sub-populations (original and validation
one) were two uncharacterized proteins (J9NXL3 and F1Q3K7) (Fig. 3).
BLAST analysis revealed that the identified “uncharacterized protein”
(J9NXL3) presented 99.3% homology with the haemoglobin alpha
subunit from Canis lupus familiaris (P60530) and the other “un-
characterized protein” (F1Q3K7) presented 100% homology with the
lipocalin-Can f6 allergen from Canis lupus familiaris (H2B3G5).
4. Discussion
This is the first study evaluating the salivary proteome in obese dogs
with and without obesity-related metabolic dysfunction (ORMD and
non-ORMD, respectively). Initially, saliva from a sub-population of 12
dogs (6 with and 6 without ORMD) were analysed, with a subsequent
analysis being performed in an independent sub-population of 12 dif-
ferent dogs (6 with and 6 without ORMD) for validation of results.
In the present study, 83% of the detected proteins were reported
previously in canine saliva using proteomic approaches [23], while 51
identified proteins have never been reported before for dog saliva. At
least in part, this can be attributed to different methodologies and dog
breeds used among the diverse studies, since different salivary pro-
teomes were described in dogs of different breeds [24,25].
Analysis in both sub-populations of dogs allowed the observation of
nine salivary proteins with increased abundance in ORMD group. These
proteins are involved in stress/oxidation defence [superoxide dismutase
[CueZn], glutathione-S-transferase, heat shock protein 70 (Hsp70)],
related with the glycolytic pathways (glycolysis - glucose 6-phosphate
isomerase, phosphoglycerate mutase; and pentose phosphate pathway -
Glucose-6-phosphate 1-dehydrogenase), cytoskeletal dynamics (protein
S100, actinin α-4), protein degradation (cathepsin D) and transport
(lipocalin, haemoglobin alpha subunit).
Metabolic syndrome is known to be related with oxidative stress, a
condition in which an imbalance results between the production and
inactivation of reactive oxygen species [26]. As such, it is under-
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Fig. 1. Salivary proteins presenting consistent variations between ORMD and non-ORMD groups in both the screening and the validation assays.
Fig. 2. Partial Least Square Determinant Analysis (PLS-DA) model for dog saliva samples of original sub-population [non-ORMD (n= 5, Δ) vs. ORMD (n= 6, +)]. X
and Y axis show principal component 1 (PC1) and principal component 2 (PC2), respectively, and the contribution of each of them for explaining the total variance.
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increased in the saliva of ORMD group of dogs. Superoxide dismutase is
a major antioxidant enzyme. Al-Rawi [27] reported an increase in the
levels of this enzyme in serum and saliva of diabetic persons. This in-
crease was suggested to be due to the increase in free radical production
and a pro-oxidant environment, in diabetes, with the reaction of the
antioxidant defence system to counter balance it. In the case of obesity,
this increase in the levels of superoxide dismutase appears to be only in
initial states and when obesity persists there is a depletion of anti-
oxidant sources, including this enzyme [28].
Glutathione S transferase belongs to a class of proteins involved in
detoxification of endogenous and exogenous compounds. This enzyme,
in concert with antioxidant systems modulate oxidative stress asso-
ciated with diabetes mellitus. All of the animals tested in the present
study (in both sub-populations) that were diagnosed with ORMD were
hyperglycemic and the increase in the levels of this enzyme in their
saliva goes in line with studies reporting higher serum levels of glu-
tathione-S-transferase associated with increased levels of glycated
haemoglobin [29]. Additionally, to the two proteins refereed before,
the increase in the levels of Hsp70 also supports the thought of aug-
mented oxidative stress in ORMD dogs. Heat shock proteins are en-
dogenous highly conserved molecules produced by cells when exposed
to a cell stressor. Increased levels of Hsp70 were observed to be in-
creased in patients with diabetes mellitus in different studies [30,31].
Although protein S100 is involved in cytoskeletal dynamics, this
protein can be released from cytoplasm in response to tissue/cell da-
mage. S100 proteins serve as danger signal and are crucial in regulating
immune homeostasis and inflammation [32]. In same line, in previous
proteomic-based studies in serum, altered immune system in dogs with
ORMD was observed [7,10].
The proteins glucose 6-phosphate isomerase and phosphoglycerate
mutase participate in glycolysis and were observed to be augmented in
the saliva of ORMD dogs. Glucose 6-phosphate isomerase catalyses the
interconversion of glucose-6 phosphate and fructose-6 phosphate,
whereas phosphoglycerate mutase catalyses the transfer of phosphate
groups from 3-phosphoglycerate to 2-phosphoglycerate. The reason
why these two enzymes were observed to be increased in the saliva of
ORMD dogs needs further clarification. Although glycolysis appears as a
potential route for lowering hyperinsulinemia, its occurrence appears to
be different in type 1 and type 2 diabetes. Whereas in the first, insulin
deficiency results in lowering glycolysis, in type 2 diabetes, hyper-
insulinemia brings about a compensatory increase in rates of glycolysis
in the liver, adipose tissue, and pancreatic β cells [33], until tissues
became resistant to insulin.
The levels of the enzyme glucose-6-phosphate dehydrogenase, in-
volved in the pentose phosphate pathway, were already reported to be
increased in diabetes [34]. The activity of this enzyme is related with
the production of NADPH, being this last an important intracellular
reductant, counteracting oxidative stress. It is possible that, at an initial
phase of diabetes, increases in this enzyme prevent the oxidative stress
known to associate to the development of diabetes and metabolic
syndrome. Xu et al. [35] reported that chronic hyperglycemia causes
inhibition of glucose-6-phosphate dehydrogenase, resulting in in-
creased oxidative stress.
Through PLS-DA it was also observed the contribution of Can f6
allergen to separate the two groups (ORMD vs. Non ORMD), with this
protein decreased in ORMD group. Can f 6 is a dog allergen from the
family of lipocalins. Lipocalins owe their name to the fact that they
usually carry lipids (or other hydrophobic compounds). These are im-
portant allergens to humans, existent in dog saliva [36]. The amounts of
lipocalin are usually increased in obesity [37].
The limitations of this study include a relatively low number of
animals used, although it is in line with previously reported studies
based on proteomic approach [24]. The need for a considerable number
of animals was highlighted by the different results obtained for the two
sub-populations of animals used in this study. It was necessary to in-
crease the number of animals to access differences in salivary proteins
that were not previously observed using only six animals per group. The
studied animals were from different households with different diets,
Fig. 3. Variable Importance in Projection (VIP) represents the contribution score of the proteins that mostly contribute to the separation between non-ORMD and
ORMD groups (A – original sub-population; B – sub-population used for validation). Circles highlight the proteins with similar behaviour in both sub-populations. The
black and white boxes on the right indicate the relative concentrations of the corresponding protein in each group under study. 0 – non-ORMD; 1 –ORMD.
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environmental conditions and care. Although this could contribute to
increase variability, this had the advantage of permitting to evaluate a
naturally occurring ORMD and get a true clinical picture. Furthermore,
ideally a validation of the analytes of interest detected in this study
would be desirable in a population of 200–300 dogs, with ORMD, to get
an estimated power of 75%.
5. Conclusion
In the present study, salivary proteomes of dogs with and without
ORMD were compared and nine proteins with different abundance le-
vels were identified, with two additional proteins observed (using PLS-
DA multivariate model) as contributing to separating groups. Among
these, proteins involved in glycolysis, immune system and oxidative
stress were increased in the saliva of ORMD animals.
Saliva is a fluid presenting variations among individual animals,
breeds, through the day and with different stimulation. Moreover,
metabolic syndrome includes different combinations of diseases. Even
with these factors leading to variability in dogs with ORMD, the re-
ferred salivary proteins were observed to differ between groups. As
such, the present study shows the potential of saliva to study metabolic
diseases in dogs. However, further long-scale studies are needed to
confirm these findings and to increase the knowledge about the possible
associations between these proteins and ORMD in dogs.
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